Faruqi and Faruqui, LLP Logo
Share this page

Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ:ARWR

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Arrowhead Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Arrowhead Pharmaceuticals, Inc. (“Arrowhead” or the “Company”) (NASDAQ:ARWR) of the January 17, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased Arrowhead common stock between May 11, 2015 and November 8, 2016 (the “Class Period”).  The case, Meller v. Arrowhead Pharmaceuticals, Inc. et al, No. 2:16-cv-08505 was filed on November 15, 2016.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) ARC-520, an RNAi-based therapeutic to treat chronic hepatitis B virus infection, was fatal at certain doses; (ii) consequently, the U.S. Food & Drug Administration (“FDA”) was unlikely to approve ARC-520 as a hepatitis B treatment; (iii) the Company overstated the approval prospects and commercial viability of ARC-520; and (iv) as a result, Arrowhead’s public statements were materially false and misleading.

Specifically, during after-market hours on November 8, 2016, Arrowhead issued a press release announcing that the FDA would be placing a clinical hold on the Company’s Heparc- 2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study.

After this announcement, Arrowhead’s share price fell from $6.11 per share on November 8, 2016 to a closing price of $4.20 on November 9, 2016—a $1.91 or a 31.26% drop.

Take Action

If you invested in Arrowhead common stock or options between May 11, 2015 and November 8, 2016 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Arrowhead’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Arrowhead Pharmaceuticals, Inc. (ARWR)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 11/16/2016

Class Period:

  • 05/11/2015 - 11/08/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.